Literature DB >> 19223493

Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.

Guanzhen Yu1, Jiejun Wang, Ying Chen, Xi Wang, Jun Pan, Gang Li, Zhiliang Jia, Qiang Li, James C Yao, Keping Xie.   

Abstract

PURPOSE: We determined the expression of mammalian target of rapamycin (mTOR) and its activated form, p-mTOR, in Chinese patients with gastric cancer and its clinical effects and underlying mechanisms. EXPERIMENTAL
DESIGN: Tissue microarray blocks containing gastric cancer tissue and matched noncancer gastric tissue specimens obtained from 1,072 patients were constructed. Expression of total mTOR and p-mTOR in these specimens was analyzed using immunohistochemical studies and confirmed by Western blotting.
RESULTS: The overall rates of total mTOR and p-mTOR overexpression were 50.8% (545 of 1,072) and 46.5% (499 of 1,072), respectively. The p-mTOR overexpression was significantly correlated with total mTOR overexpression. Overexpression of total mTOR protein was significantly correlated with tumor differentiation, T1/T2 tumors, and stage I/II/III disease, whereas p-mTOR overexpression was significantly correlated with lymph node metastasis and all stage disease. The Cox proportional hazards model revealed that the overexpression of p-mTOR, but not total mTOR, was an independent prognostic factor for gastric cancer. The overexpression of p-mTOR also predicted the angiogenic phenotype of human gastric cancer and regulated angiogenesis of gastric cancer cells.
CONCLUSIONS: Increased activation of mTOR is frequent in human gastric cancer and overexpression of p-mTOR is an independent prognostic factor, suggesting that mTOR pathway could be a potential target for therapy of this malignancy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223493     DOI: 10.1158/1078-0432.CCR-08-2138

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  77 in total

1.  Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report.

Authors:  Sin Jen Ong; Marissa Teo; Kiat Hon Lim; Su Pin Choo; Han Chong Toh
Journal:  Oncologist       Date:  2010-08-26

Review 2.  Molecular-targeted first-line therapy for advanced gastric cancer.

Authors:  Huan Song; Jianwei Zhu; DongHao Lu
Journal:  Cochrane Database Syst Rev       Date:  2016-07-19

3.  Notch signaling regulates gastric antral LGR5 stem cell function.

Authors:  Elise S Demitrack; Gail B Gifford; Theresa M Keeley; Alexis J Carulli; Kelli L VanDussen; Dafydd Thomas; Thomas J Giordano; Zhenyi Liu; Raphael Kopan; Linda C Samuelson
Journal:  EMBO J       Date:  2015-08-12       Impact factor: 11.598

4.  Expression and clinical significance of mammalian target of rapamycin/P70 ribosomal protein S6 kinase signaling pathway in human colorectal carcinoma tissue.

Authors:  Qingjun Lu; Jieshu Wang; Gang Yu; Tianhua Guo; Chun Hu; Peng Ren
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

5.  Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

Authors:  Hilda Wong; Thomas Yau
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

Review 6.  Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome.

Authors:  Sun Min Lim; Jae Yun Lim; Jae Yong Cho
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

7.  Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2.

Authors:  Ming Zhuang; Qin Shi; Xiuwei Zhang; Yongbin Ding; Liuqun Shan; Xia Shan; Jiaqi Qian; Xin Zhou; Zebo Huang; Wei Zhu; Yin Ding; Wenfang Cheng; Ping Liu; Yongqian Shu
Journal:  Tumour Biol       Date:  2014-12-10

8.  Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

Authors:  Atsushi Ohtsu; Jaffer A Ajani; Yu-Xian Bai; Yung-Jue Bang; Hyun-Cheol Chung; Hong-Ming Pan; Tarek Sahmoud; Lin Shen; Kun-Huei Yeh; Keisho Chin; Kei Muro; Yeul Hong Kim; David Ferry; Niall C Tebbutt; Salah-Eddin Al-Batran; Heind Smith; Chiara Costantini; Syed Rizvi; David Lebwohl; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

9.  Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer.

Authors:  Da-zhi Xu; Qi-rong Geng; Ying Tian; Mu-yan Cai; Xin-juan Fang; You-qing Zhan; Zhi-wei Zhou; Wei Li; Ying-bo Chen; Xiao-wei Sun; Yuan-xiang Guan; Yuan-fang Li; Tong-yu Lin
Journal:  BMC Cancer       Date:  2010-10-07       Impact factor: 4.430

Review 10.  Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.

Authors:  Marwa Matboli; Sarah El-Nakeep; Nourhan Hossam; Alaa Habieb; Ahmed E M Azazy; Ali E Ebrahim; Ziad Nagy; Omar Abdel-Rahman
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.